Navigation Links
Adeona's Alzheimer's Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurology's 63rd Annual Meeting
Date:2/8/2011

ption medical food. All 60 patients are enrolled in the clinical study evaluating reaZin. In this randomized, double-blind, placebo-controlled study, patients are assessed 3 and 6 months after they begin the once-daily oral treatment or matching placebo. These 60 patients should complete their 6 month treatment by the end of March 2011. If successful, Adeona expects to make its reaZin product commercially available as a prescription medical food for patients suffering from Alzheimer's disease and mild cognitive impairment.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical study and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks a
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
9. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
10. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
11. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 ... My Diabetes Emergency Plan at the 2015 @NatHurricaneCon ... to be prepared to manage your #diabetes before emergencies ... (ACE) – the charitable, educational and scientific arm of ... joined forces with Lilly Diabetes to share the ...
(Date:3/30/2015)... 30, 2015  Check-Cap Ltd. (NASDAQ: CHEK ), ... development of a preparation-free ingestible imaging capsule that utilizes ... today that its CEO, Guy Neev , will ring ... day.  Neev and Check-Cap will participate in the closing ... public offering and simultaneous private placement which raised a ...
(Date:3/30/2015)... and ORANGEBURG, N.Y., March 30, 2015  Uroplasty, ... VSCI ) shareholders have voted at the ... to approve the previously announced agreement and plan ... "We are pleased with the outcome of today,s ... both shareholder groups for approving the merger agreement," ...
Breaking Medicine Technology:Preparation Is Personal for Those with Chronic Illnesses 2Preparation Is Personal for Those with Chronic Illnesses 3Preparation Is Personal for Those with Chronic Illnesses 4Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4
... , EAST HANOVER, N.J., Oct. 12 Novartis Pharma AG ... rights to Fanapt(TM) (iloperidone), a new oral medication ... (FDA) for the acute treatment of adults with schizophrenia. Novartis ... early 2010. , As part of the agreement with ...
... 12 Hospira, Inc. (NYSE: HSP ), a leading ... the company will present at the Credit Suisse 18th Annual ... , The presentation is scheduled to begin at 8:00 a.m. ... will be available to all interested parties through a live ...
Cached Medicine Technology:Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 2Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 3Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 4Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 5Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 6Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 7Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 8
(Date:3/31/2015)... A' Design Award and Competition is pleased to announce ... has been announced as a winner of the Golden A' ... Competition Category. , Details of Food Feeder Plus, Justin ... Food Feeder Plus demonstrated “The Food Feeder Plus not only ... for the parents. Babies can hold by themselves and suck ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 The ... Consumables (Reagents, Standards), Test Type (APTT, Prothrombin Time/INR, ... Institute, Hospital)–Forecast to 2019” analyzes and studies the ... North America, Europe, Asia-Pacific and the Rest of ... analyzers market is expected to reach $3.58 billion ...
(Date:3/31/2015)... FL (PRWEB) March 31, 2015 ... Sickness Insurance programs, issues a travel advisory to all ... care costs in the United States are higher than ... even in developed countries. For example, a coronary ... the same procedure costs about $34,358 . Visitors ...
(Date:3/31/2015)... 31, 2015 My Positive Perspective host Jason ... to discuss the Month of Man event. At the start ... Month of Man event?” Toy replies, “The Month of Man ... that came from repetitive brain storming. At the corner stone ... with it.” Toy continues, “From baseball pitching and sunflower seed ...
(Date:3/31/2015)... Safeware has been recognized as a ... an awards program presented by Columbus Business First. , ... program, held on March 10, 2015. These winning organizations ... outstanding health and wellness initiatives. , “These 30 ... environment for their associates. Business Frist, OhioHealth and our ...
Breaking Medicine News(10 mins):Health News:Justin Cheung wins Golden in A' International Baby Products Design Awards 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 3Health News:My Positive Perspective Releases Episode Discussing the Month of Man Event 2Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2
... Board to Access State Funding, WOODLAND, Calif., Sept. ... Supervisors on Tuesday to increase funding for In-Home,Supportive Services, ... low-income seniors and people with disabilities. Workers represented ... the county for a new contract to cover the,1,300 ...
... have stood stubbornly behind President Bush on,issue after issue ... his threat,to veto health care for low-income children. America,s ... Romney and Fred Thompson veto,the children,s health care bill ... came up for discussion during an August debate in ...
... ... Area; 32% of HIV Cases in ... Are Female, ST. PETERSBURG, Fla., Sept. 25 /PRNewwire-USNewswire/ -- The following,was released today by the AIDS ... Thursday, September 27, 20077:00pm, Where: Poynter Park ...
... future, quick diagnoses should mean better treatment, experts say ... pattern of brain activity could be a sign of ... that as new treatments for Alzheimer,s become available, spotting ... team at Duke University Medical Center in Durham, N.C., ...
... less likely to develop diabetes, study says, , , TUESDAY, Sept. ... type 1 diabetes might be able to prevent the disease ... study suggests. , Reporting in the Sept. 26 issue of ... from the University of Colorado found that high-risk children with ...
... , , TUESDAY, Sept. 25 (HealthDay News) -- People newly ... normal incidence of colorectal tumors and cancers, a study ... and the heart disease "probably develop through the mechanism ... the University of Hong Kong that,s published in the ...
Cached Medicine News:Health News:Homecare Workers to Supervisors: Preserve Care of our Most Vulnerable 2Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 2Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 3Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 4Health News:St. Petersburg: Candlelight Vigil to Raise Awareness of Florida HIV/AIDS Crisis, Honor Lives Lost 2Health News:St. Petersburg: Candlelight Vigil to Raise Awareness of Florida HIV/AIDS Crisis, Honor Lives Lost 3Health News:Brain Activity Might Point to Early Alzheimer's 2Health News:Omega-3s Guard Against Type 1 Diabetes 2Health News:Omega-3s Guard Against Type 1 Diabetes 3Health News:Study Links Coronary Disease, Colon Cancer 2
... Injectable was designed to provide the surgeon with ... of surgical complications during cataract and retinal surgery. ... small and medium sized pupils which allows expansion ... iris sphincter during surgery, and allows the pupil ...
... Laminar Flow Unit is a flexible, total solution. ... to operating theaters since 1983. A major part ... and extensive experience from all the different areas ... product , ,Kojair Tech Oy is a comprehensive ...
Provides stable positioning of the knee during surgery....
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
Medicine Products: